Authors
Latest:
Lung Cancer Drugs in Development to Address Resistance MutationsNathan Pennell, MD, PhD, discusses the importance of developing drugs based on resistance to previous treatments in patients with non–small cell lung cancer.
Latest:
Managing High-Risk Follicular LymphomaNathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.
Latest:
Emerging Targeted Therapies in Marginal Zone LymphomaNathan H. Fowler, MD, discusses the latest addition to the treatment landscape for marginal zone lymphoma.
Latest:
The Future of Myelodysplastic SyndromeAn oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.
Latest:
Unmet Needs for Patients With AMLNaval G. Daver, MD, discusses the unmet needs that still exist in the treatment of acute myeloid leukemia.
Latest:
BPDCN: Future Directions in CareClosing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Latest:
Findings of the SIRFLOX Study in Metastatic Colorectal CancerNavesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study in patients with metastatic colorectal cancer (mCRC).
Latest:
Real-World Survival Analysis of Apalutamide vs Enzalutamide in mCSPCNeal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.
Latest:
Dr. Neal Young on the Evolving Treatment for Patients Diagnosed With Aplastic AnemiaNeal Young, MD, discusses the advancement of treatment for aplastic anemia. Young said aplastic anemia used to kill almost all patients diagnosed with the disease within a year.
Latest:
Novel Treatment Options for <em>T790M</em>-Mutant Non-Small Cell Lung CancerDespite initial clinical benefit of erlotinib and geftinib, overall efficacy of these agents is limited by emergence of drug-resistance mutations, including the gatekeeper T790M mutation.
Latest:
Regaining Control of the Cell Cycle With CDK 4/6 Inhibitors: A Promising Targeted Therapy for Breast CancerTherapies targeted to tumor biology hold the promise of improved outcomes for patients with breast cancer.
Latest:
Addressing Unmet Needs in Metastatic Hormone-Sensitive Prostate CancerNeeraj Agarwal, MD, discusses some of the unmet needs that exist in the prostate cancer space.
Latest:
Addressing Challenges for Patients With Relapsed CLLNeil E. Kay, MD, a professor of medicine at the Mayo Clinic, discusses the challenges that arise when treating a patient with relapsed chronic lymphocytic leukemia (CLL). Most times, responses in this setting are short lived.
Latest:
Validating the Link Between Obesity and Breast Inflammation in Women with Breast CancerNeil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses a study presented at the 2013 San Antonio Breast Cancer Symposium that further validated the link between obesity and breast inflammation in women with breast cancer.
Latest:
Dr. Nicholas A. Butowski on Convection-Enhanced Delivery of Nanoliposomal Irinotecan in Brain CancerNicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Latest:
Comparing Impact of Panel Composition on Tumor Mutational Burden CalculationNicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.
Latest:
Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade GliomaNicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
Latest:
Rationale for Phase III PROSPECT Trial in Prostate CancerNicholas J. Vogelzang, MD, a medical oncologist at the Comprehensive Cancer Centers of Nevada, discusses the rationale behind conducting the PROSPECT trial in patients with relapsed prostate cancer. Patients enrolled in this study had prostate cancer return after hormonal ablation.
Latest:
Evolving Treatment Landscape for Patients With Renal Cell CarcinomaNicholas J. Vogelzang, MD, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma treatment landscape.
Latest:
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast CancerThe optimal neoadjuvant chemotherapy regimen in triple-negative breast cancer has not been clearly defined. Achieving a pathologic complete response provides important prognostic information, and, especially in TNBC, is considered a surrogate endpoint for event-free survival.
Latest:
An Analysis of the PALOMA-3 TrialNicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.
Latest:
Understanding the Role of Palliative Care in Cancer TreatmentIn an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.
Latest:
Two BRAF Fusions Discovered in Some Pan-Negative MelanomasThe discovery of two unique molecular targets known to speed skin-cancer growth has researchers excited that they might soon understand and develop genetic therapies geared toward some of medicine’s most untreatable melanomas.
Latest:
The Role of Plasma as a Potential Alternative to EGFR Mutation Analysis in NSCLCNicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the recent data showing that plasma can act as a potential alternative to EGFR mutation analysis in the treatment of patients with non-small cell lung cancer, as well as the current demands for the use of liquid biopsies in this type of treatment.
Latest:
A Step Forward in c-Met-Targeted Therapy in NSCLCNicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.
Latest:
Long-Term Follow-Up Results From the MURANO Trial in CLLNicole Lamanna, MD, discusses the significance of the 3-year follow-up data from the MURANO trial in patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Rationale for Combining a Modified IL-2 and Nivolumab in MelanomaNikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.
